|Related Categories||A-AM, Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Biochemicals and Reagents, Cell Biology,|
|color||white to off-white|
|solubility||DMSO: >50 mg/mL|
Agomelatine is an extremely potent agonist at both melatonin receptors (MT1 and MT2), with additional antagonism at 5HT2C. It is a novel antidepressant with many desired in vivo properties, including neuroprotection and neurogenesis in depression-sensitive brain areas. Agomelatine′s efficacy appears to be due to both melatonergic and serotonergic properties. In neurogenesis assays, both in vitro and in vivo, the compound effects were differentially affected by antagonists for MT1/MT2 and 5HT2C, demonstrating actions through all three receptors.
A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. Demyttenaere K, Corruble E, Hale A, et al. CNS Spectr. 18(3), 163-70, (2013)
Melatonin analogue agomelatine reduces rabbit's intraocular pressure in normotensive and hypertensive conditions. Martínez-Águila A, Fonseca B, Bergua A, et al. Eur. J. Pharmacol. 701(1-3), 213-7, (2013)
Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control. Kasper S, Corruble E, Hale A, et al. Int. Clin. Psychopharmacol. 28(1), 12-9, (2013)
Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. Stein DJ, Ahokas A, Albarran C, et al. J. Clin. Psychiatry 73(7), 1002-8, (2012)
Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece. Maniadakis N, Kourlaba G, Mougiakos T, et al. BMC Health Serv. Res. 13, 173, (2013)
Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine. Goodwin GM, Boyer P, Emsley R, et al. Int. Clin. Psychopharmacol. 28(1), 20-8, (2013)
Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Soumier, A., et Al. Neuropsychopharmacology 34, 2390-2403, (2009)
Agomelatine, a melatonin receptor agonist with 5-HT(2C) receptor antagonist properties, protects the developing murine white matter against excitotoxicity. Gressens, P., et Al. Eur. J. Pharmacol. 588, 58-63, (2008)
Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture. Descamps, A., et Al. Psychopharmacology 205, 93-106, (2009)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Need larger quantities for your development, manufacturing or research applications?